Loading…
Lobbying Spend
—
Filings
54
Firms Hired
1
Active Period
2013–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Work on drug shortage issues affecting outpatient and inpatient settings. Also work on drug visibility supply chain issues including S. 3788, "the CLEAR Labels Act."
Client expense: — · Firm income: $50,000
Matched citations: S. 3788
Work on drug shortage issues affecting outpatient and inpatient settings. Also work on drug visibility supply chain issues including S. 3788, "the CLEAR Labels Act."
Client expense: — · Firm income: $50,000
Matched citations: S. 3788
Work on medical supply chain issues impacting drug shortages for inpatient facilities. Advocate for SNS product rotation, buffer stock, private sector collaboration and updated FDA drug shortage warnings. This includes work on S. 2510, the RAPID Reserve Act.
Client expense: — · Firm income: $40,000
Matched citations: S. 2510
Work on medical supply chain issues impacting drug shortages for inpatient facilities. Advocate for SNS product rotation, buffer stock, private sector collaboration and updated FDA drug shortage warnings. This includes work on S. 2510, the RAPID Reserve Act.
Client expense: — · Firm income: $40,000
Matched citations: S. 2510
Work on medical supply chain issues impacting drug shortages for inpatient facilities. Advocate for SNS product rotation, buffer stock, private sector collaboration and updated FDA drug shortage warnings. This includes work on S. 2510, the RAPID Reserve Act.
Client expense: — · Firm income: $40,000
Matched citations: S. 2510
Providing for the concurrence by the House in the Senate amendment to H.R. 4366, with an amendment.
2024 · first_quarter · Firm: THE D MAJOR GROUP
Work on reauthorization of the Pandemic All Hazards Preparedness Act, including H.Res. 1061 the "Consolidated Appropriations Act of 2024,"
Client expense: — · Firm income: $40,000
Matched citations: H.Res. 1061
Work on medical supply chain issues impacting drug shortages for inpatient facilities. Advocate for SNS product rotation, buffer stock, private sector collaboration and updated FDA drug shortage warnings. This includes work on S. 2510, the RAPID Reserve Act.
Client expense: — · Firm income: $40,000
Matched citations: S. 2510
Work on medical supply chain issues impacting drug shortages for inpatient facilities. Advocate for SNS product rotation, buffer stock, private sector collaboration and updated FDA drug shortage warnings. This includes work on S. 2510, the RAPID Reserve Act.
Client expense: — · Firm income: $40,000
Matched citations: S. 2510
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: THE D MAJOR GROUP
Work on Strategic National Stockpile and other emergency preparedness items included in HR 2617, the "Consolidated Appropriations Act of FY23." Monitor impact of drug pricing reforms as passed in HR 5376, the "Inflation Reduction Act."
Client expense: — · Firm income: $40,000
Matched citations: HR 2617
Medical Supplies for Pandemics Act of 2021
2022 · fourth_quarter · Firm: THE D MAJOR GROUP
Monitor H.R. 3463 and S. 1695, the Medical Supplies for Pandemics Act. Also work on supply chain issues related to S. 1260, the US Innovation and Competition Act, as well as SNS and ASPR issues contained in S. 3799, the PREVENT Pandemics Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 3463
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: THE D MAJOR GROUP
Work on Strategic National Stockpile and other emergency preparedness items included in HR 2617, the "Consolidated Appropriations Act of FY23." Monitor impact of drug pricing reforms as passed in HR 5376, the "Inflation Reduction Act."
Client expense: — · Firm income: $40,000
Matched citations: HR 5376
United States Innovation and Competition Act of 2021
2022 · fourth_quarter · Firm: THE D MAJOR GROUP
Monitor H.R. 3463 and S. 1695, the Medical Supplies for Pandemics Act. Also work on supply chain issues related to S. 1260, the US Innovation and Competition Act, as well as SNS and ASPR issues contained in S. 3799, the PREVENT Pandemics Act.
Client expense: — · Firm income: $40,000
Matched citations: S. 1260
Eliminating Barriers to Rural Internet Development Grant Eligibility Act
2022 · fourth_quarter · Firm: THE D MAJOR GROUP
Monitor H.R. 3463 and S. 1695, the Medical Supplies for Pandemics Act. Also work on supply chain issues related to S. 1260, the US Innovation and Competition Act, as well as SNS and ASPR issues contained in S. 3799, the PREVENT Pandemics Act.
Client expense: — · Firm income: $40,000
Matched citations: S. 1695
Monitor H.R. 3463 and S. 1695, the Medical Supplies for Pandemics Act. Also work on supply chain issues related to S. 1260, the US Innovation and Competition Act, as well as SNS and ASPR issues contained in S. 3799, the PREVENT Pandemics Act.
Client expense: — · Firm income: $40,000
Matched citations: S. 3799
Medical Supplies for Pandemics Act of 2021
2022 · third_quarter · Firm: THE D MAJOR GROUP
Monitor H.R. 3463 and S. 1695, the Medical Supplies for Pandemics Act. Also work on supply chain issues related to S. 1260, the US Innovation and Competition Act, as well as SNS and ASPR issues contained in S. 3799, the PREVENT Pandemics Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 3463
Inflation Reduction Act of 2022
2022 · third_quarter · Firm: THE D MAJOR GROUP
Work on drug shortage issues, including provisions related to the FDA User Fee Reauthorization measure as passed in HR 6833, the "Continuing Appropriations & Ukraine Supplemental Appropriations Act." Monitor drug pricing legislation included in HR 5376, the "Inflation Reduction Act."
Client expense: — · Firm income: $40,000
Matched citations: HR 5376
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · third_quarter · Firm: THE D MAJOR GROUP
Work on drug shortage issues, including provisions related to the FDA User Fee Reauthorization measure as passed in HR 6833, the "Continuing Appropriations & Ukraine Supplemental Appropriations Act." Monitor drug pricing legislation included in HR 5376, the "Inflation Reduction Act."
Client expense: — · Firm income: $40,000
Matched citations: HR 6833
United States Innovation and Competition Act of 2021
2022 · third_quarter · Firm: THE D MAJOR GROUP
Monitor H.R. 3463 and S. 1695, the Medical Supplies for Pandemics Act. Also work on supply chain issues related to S. 1260, the US Innovation and Competition Act, as well as SNS and ASPR issues contained in S. 3799, the PREVENT Pandemics Act.
Client expense: — · Firm income: $40,000
Matched citations: S. 1260
Eliminating Barriers to Rural Internet Development Grant Eligibility Act
2022 · third_quarter · Firm: THE D MAJOR GROUP
Monitor H.R. 3463 and S. 1695, the Medical Supplies for Pandemics Act. Also work on supply chain issues related to S. 1260, the US Innovation and Competition Act, as well as SNS and ASPR issues contained in S. 3799, the PREVENT Pandemics Act.
Client expense: — · Firm income: $40,000
Matched citations: S. 1695
Monitor H.R. 3463 and S. 1695, the Medical Supplies for Pandemics Act. Also work on supply chain issues related to S. 1260, the US Innovation and Competition Act, as well as SNS and ASPR issues contained in S. 3799, the PREVENT Pandemics Act.
Client expense: — · Firm income: $40,000
Matched citations: S. 3799
Medical Supplies for Pandemics Act of 2021
2022 · second_quarter · Firm: THE D MAJOR GROUP
Monitor H.R. 3463 and S. 1695, the Medical Supplies for Pandemics Act. Also work on supply chain issues related to S. 1260, the US Innovation and Competition Act, as well as SNS and ASPR issues contained in S. 3799, the PREVENT Pandemics Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 3463
Food and Drug Amendments of 2022
2022 · second_quarter · Firm: THE D MAJOR GROUP
Work on drug shortage issues. Also monitor HR 7667, the Food and Drug Amendments Act of 2022; as well as S. 4348, the Food and Drug Administration Safety and Landmark Advancements Act.
Client expense: — · Firm income: $40,000
Matched citations: HR 7667
United States Innovation and Competition Act of 2021
2022 · second_quarter · Firm: THE D MAJOR GROUP
Monitor H.R. 3463 and S. 1695, the Medical Supplies for Pandemics Act. Also work on supply chain issues related to S. 1260, the US Innovation and Competition Act, as well as SNS and ASPR issues contained in S. 3799, the PREVENT Pandemics Act.
Client expense: — · Firm income: $40,000
Matched citations: S. 1260
Eliminating Barriers to Rural Internet Development Grant Eligibility Act
2022 · second_quarter · Firm: THE D MAJOR GROUP
Monitor H.R. 3463 and S. 1695, the Medical Supplies for Pandemics Act. Also work on supply chain issues related to S. 1260, the US Innovation and Competition Act, as well as SNS and ASPR issues contained in S. 3799, the PREVENT Pandemics Act.
Client expense: — · Firm income: $40,000
Matched citations: S. 1695
Monitor H.R. 3463 and S. 1695, the Medical Supplies for Pandemics Act. Also work on supply chain issues related to S. 1260, the US Innovation and Competition Act, as well as SNS and ASPR issues contained in S. 3799, the PREVENT Pandemics Act.
Client expense: — · Firm income: $40,000
Matched citations: S. 3799
Source: Senate LDA